ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules

Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg of mometasone furoate.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of indacaterol (as acetate) and 62.5 mcg of mometasone furoate.

Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules

Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg of mometasone furoate.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of indacaterol (as acetate) and 127.5 mcg of mometasone furoate.

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules

Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg of mometasone furoate.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of indacaterol (as acetate) and 260 mcg of mometasone furoate.

Excipient(s) with known effect

Each capsule contains approximately 25 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Inhalation powder, hard capsule (inhalation powder).

Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules

Transparent (uncoloured) capsules containing a white powder, with the product code “IM150-80” printed in blue above one blue bar on the body and with the product logo printed in blue and surrounded by two blue bars on the cap.

Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules

Transparent (uncoloured) capsules containing a white powder, with the product code “IM150-160” printed in grey on the body and with the product logo printed in grey on the cap.

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules

Transparent (uncoloured) capsules containing a white powder, with the product code “IM150-320” printed in black above two black bars on the body and with the product logo printed in black and surrounded by two black bars on the cap.
4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.

4.2 Posology and method of administration

Posology

Adults and adolescents aged 12 years and over
The recommended dose is one capsule to be inhaled once daily.

Patients should be given the strength containing the appropriate mometasone furoate dosage for the severity of their disease and should be regularly reassessed by a healthcare professional.

The maximum recommended dose is 125 mcg/260 mcg once daily.

Treatment should be administered at the same time of the day each day. It can be administered irrespective of the time of the day. If a dose is missed, it should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.

Special populations

Elderly population
No dose adjustment is required in elderly patients (65 years of age or older) (see section 5.2).

Renal impairment
No dose adjustment is required in patients with renal impairment (see section 5.2).

Hepatic impairment
No dose adjustment is required in patients with mild or moderate hepatic impairment. No data are available for the use of the medicinal product in patients with severe hepatic impairment, therefore it should be used in these patients only if the expected benefit outweighs the potential risk (see section 5.2).

Paediatric population
The posology in patients 12 years of age and older is the same posology as in adults. The safety and efficacy in paediatric patients below 12 years of age have not been established. No data are available.

Method of administration

For inhalation use only. The capsules must not be swallowed.

The capsules must be administered only using the inhaler provided (see section 6.6) with each new prescription.

Patients should be instructed on how to administer the medicinal product correctly. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicinal product rather than inhaling it.

The capsules must only be removed from the blister immediately before use.
After inhalation, patients should rinse their mouth with water without swallowing (see sections 4.4 and 6.6).

For instructions on use of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Deterioration of disease

This medicinal product should not be used to treat acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required. Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.

Patients should not stop treatment without physician supervision since symptoms may recur after discontinuation.

It is recommended that treatment with this medicinal product should not be stopped abruptly. If patients find the treatment ineffective, they should continue treatment but must seek medical attention. Increasing use of reliever bronchodilators indicates a worsening of the underlying condition and warrants a reassessment of the therapy. Sudden and progressive deterioration in the symptoms of asthma is potentially life-threatening and the patient should undergo urgent medical assessment.

Hypersensitivity

Immediate hypersensitivity reactions have been observed after administration of this medicinal product. If signs suggesting allergic reactions occur, in particular angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips and face), urticaria or skin rash, treatment should be discontinued immediately and alternative therapy instituted.

Paradoxical bronchospasm

As with other inhalation therapy, administration of this medicinal product may result in paradoxical bronchospasm, which can be life-threatening. If this occurs, treatment should be discontinued immediately and alternative therapy instituted.

Cardiovascular effects of beta agonists

Like other medicinal products containing beta2-adrenergic agonists, this medicinal product may produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, blood pressure and/or symptoms. If such effects occur, treatment may need to be discontinued.

This medicinal product should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2-adrenergic agonists.

Patients with unstable ischaemic heart disease, a history of myocardial infarction in last 12 months, New York Heart Association (NYHA) class III/IV left ventricular failure, arrhythmia, uncontrolled hypertension, cerebrovascular disease or history of long QT syndrome and patients being treated with medicinal products known to prolong QTc were excluded from studies in the indacaterol/mometasone furoate clinical development programme. Thus safety outcomes in these populations are considered unknown.
While beta-2-adrenergic agonists have been reported to produce electrocardiographic (ECG) changes, such as flattening of the T wave, prolongation of QT interval and ST segment depression, the clinical significance of these observations is unknown.

Long-acting beta-2-adrenergic agonists (LABA) or LABA-containing combination products such as Atecutura Breezhaler should therefore be used with caution in patients with known or suspected prolongation of the QT interval or who are being treated with medicinal products affecting the QT interval.

**Hypokalaemia with beta agonists**

Beta-2-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. In patients with severe asthma hypokalaemia may be potentiated by hypoxia and concomitant treatment, which may increase the susceptibility to cardiac arrhythmias (see section 4.5).

Clinically relevant hypokalaemia has not been observed in clinical studies of indacaterol/mometasone furoate at the recommended therapeutic dose.

**Hyperglycaemia**

Inhalation of high doses of beta-2-adrenergic agonists and corticosteroids may produce increases in plasma glucose. Upon initiation of treatment, plasma glucose should be monitored more closely in diabetic patients.

This medicinal product has not been investigated in patients with Type I diabetes mellitus or uncontrolled Type II diabetes mellitus.

**Prevention of oropharyngeal infections**

In order to reduce the risk of oropharyngeal candida infection, patients should be advised to rinse their mouth or gargle with water without swallowing it or brush their teeth after inhaling the prescribed dose.

**Systemic effects of corticosteroids**

Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations.

Possible systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataracts, glaucoma, and, more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is therefore important that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.

Visual disturbance may be reported with systemic and topical (including intranasal, inhaled and intraocular) corticosteroid use. Patients presenting with symptoms such as blurred vision or other visual disturbances should be considered for referral to an ophthalmologist for evaluation of possible causes of visual disturbances, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

This medicinal product should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections.
Excipients

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

No specific interaction studies were conducted with indacaterol/mometasone furoate. Information on the potential for interactions is based on the potential for each of the monotherapy components.

Medicinal products known to prolong the QTc interval

Like other medicinal products containing a beta₂-adrenergic agonist, this medicinal product should be administered with caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants or medicinal products known to prolong the QT interval, as any effect of these on the QT interval may be potentiated. Medicinal products known to prolong the QT interval may increase the risk of ventricular arrhythmia (see sections 4.4 and 5.1).

Hypokalaemic treatment

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta₂-adrenergic agonists (see section 4.4).

Beta-adrenergic blockers

Beta-adrenergic blockers may weaken or antagonise the effect of beta₂-adrenergic agonists. Therefore, this medicinal product should not be given together with beta-adrenergic blockers unless there are compelling reasons for their use. Where required, cardioselective beta-adrenergic blockers should be preferred, although they should be administered with caution.

Interaction with CYP3A4 and P-glycoprotein inhibitors

Inhibition of CYP3A4 and P-glycoprotein (P-gp) has no impact on the safety of therapeutic doses of Atecutra Breezhaler.

Inhibition of the key contributors of indacaterol clearance (CYP3A4 and P-gp) or mometasone furoate clearance (CYP3A4) raises the systemic exposure of indacaterol or mometasone furoate up to two-fold.

Due to the very low plasma concentration achieved after inhaled dosing, clinically significant interactions with mometasone furoate are unlikely. However, there may be a potential for increased systemic exposure to mometasone furoate when strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, nelfinavir, ritonavir, cobicistat) are co-administered.

Other long-acting beta₂-adrenergic agonists

The co-administration of this medicinal product with other medicinal products containing long-acting beta₂-adrenergic agonists has not been studied and is not recommended as it may potentiate adverse reactions (see sections 4.8 and 4.9).
4.6 Fertility, pregnancy and lactation

Pregnancy

There are insufficient data from the use of Atectura Breezhaler or its individual components (indacaterol and mometasone furoate) in pregnant women to determine whether there is a risk.

Indacaterol was not teratogenic in rats and rabbits following subcutaneous administration (see section 5.3). In animal reproduction studies with pregnant mice, rats and rabbits, mometasone furoate caused increased foetal malformations and decreased foetal survival and growth.

Like other medicinal products containing beta2-adrenergic agonists, indacaterol may inhibit labour due to a relaxant effect on uterine smooth muscle.

This medicinal product should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.

Breast-feeding

There is no information available on the presence of indacaterol or mometasone furoate in human milk, on the effects on a breast-fed infant, or on the effects on milk production. Other inhaled corticosteroids similar to mometasone furoate are transferred into human milk. Indacaterol (including its metabolites) and mometasone furoate have been detected in the milk of lactating rats.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

Reproduction studies and other data in animals did not indicate a concern regarding fertility in either males or females.

4.7 Effects on ability to drive and use machines

This medicinal product has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most common adverse reactions over 52 weeks were asthma (exacerbation) (26.9%), nasopharyngitis (12.9%), upper respiratory tract infection (5.9%) and headache (5.8%).

Tabulated list of adverse reactions

Adverse drug reactions (ADRs) are listed by MedDRA system organ class (Table 1). The frequency of the ADRs is based on the PALLADIUM study. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
### Table 1  Adverse reactions

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Adverse reactions</th>
<th>Frequency category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Nasopharyngitis</td>
<td>Very common</td>
</tr>
<tr>
<td></td>
<td>Upper respiratory tract</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Candidiasis*</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity*</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Angioedema*</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Hyperglycaemia*</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache*</td>
<td>Common</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Vision blurred</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Cataract*</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Tachycardia*</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal</td>
<td>Asthma (exacerbation)</td>
<td>Very common</td>
</tr>
<tr>
<td>disorders</td>
<td>Oropharyngeal pain*</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Dysphonia</td>
<td>Common</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash*</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Pruritus*</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue</td>
<td>Musculoskeletal pain*</td>
<td>Common</td>
</tr>
<tr>
<td>disorders</td>
<td>Muscle spasms</td>
<td>Uncommon</td>
</tr>
</tbody>
</table>

* Indicates grouping of preferred terms (PTs):

1. Oral candidiasis, oropharyngeal candidiasis.
2. Drug eruption, drug hypersensitivity, hypersensitivity, rash, rash erythematous, rash pruritic, urticaria.
3. Allergic oedema, angioedema, periorbital swelling, swelling of eyelid.
4. Blood glucose increased, hyperglycaemia.
5. Headache, tension headache.
6. Cataract, cataract cortical.
7. Heart rate increased, tachycardia, sinus tachycardia, supraventricular tachycardia.
8. Oral pain, oropharyngeal discomfort, oropharyngeal pain, throat irritation, odynophagia.
9. Drug eruption, rash, rash erythematous, rash pruritic.
10. Anal pruritus, eye pruritus, nasal pruritus, pruritus, pruritus genital.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### 4.9 Overdose

General supportive measures and symptomatic treatment should be initiated in cases of suspected overdose.

An overdose will likely produce signs, symptoms or adverse effects associated with the pharmacological actions of the individual components (e.g. tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, ventricular arrhythmias, metabolic acidosis, hypokalaemia, hyperglycaemia, suppression of hypothalamic pituitary adrenal axis function).

Use of cardioselective beta blockers may be considered for treating beta₂-adrenergic effects, but only under the supervision of a physician and with extreme caution, since the use of beta₂-adrenergic blockers may provoke bronchospasm. In serious cases, patients should be hospitalised.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics, ATC code: R03AK14

Mechanism of action

This medicinal product is a combination of indacaterol, a long-acting beta₂-adrenergic agonist (LABA), and mometasone furoate, an inhaled synthetic corticosteroid (ICS).

Indacaterol
The pharmacological effects of beta₂-adrenoceptor agonists, including indacaterol, are at least in part attributable to increased cyclic-3’, 5’-adenosine monophosphate (cyclic AMP) levels, which cause relaxation of bronchial smooth muscle.

When inhaled, indacaterol acts locally in the lung as a bronchodilator. Indacaterol is a partial agonist at the human beta₂-adrenergic receptor with nanomolar potency. In isolated human bronchus, indacaterol has a rapid onset of action and a long duration of action.

Although beta₂-adrenergic receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta₁-receptors are the predominant receptors in the human heart, there are also beta₂-adrenergic receptors in the human heart comprising 10% to 50% of the total adrenergic receptors.

Mometasone furoate
Mometasone furoate is a synthetic corticosteroid with high affinity for glucocorticoid receptors and local anti-inflammatory properties. In vitro, mometasone furoate inhibits the release of leukotrienes from leukocytes of allergic patients. In cell culture, mometasone furoate demonstrated high potency in inhibition of synthesis and release of IL-1, IL-5, IL-6 and TNF-alpha. It is also a potent inhibitor of leukotriene production and of the production of the Th2 cytokines IL-4 and IL-5 from human CD4+ T-cells.

Pharmacodynamic effects

The pharmacodynamic response profile of this medicinal product is characterised by rapid onset of action within 5 minutes after dosing and sustained effect over the 24-hour dosing interval, as evidenced by improvements in trough forced expiratory volume in the first second (FEV₁) improvements versus comparators 24 hours after dosing.

No tachyphylaxis to the lung function benefits of this medicinal product was observed over time.

QTc interval
The effect of this medicinal product on the QTc interval has not been evaluated in a thorough QT (TQT) study. For mometasone furoate, no QTc-prolonging properties are known.
Clinical efficacy and safety

Two phase III randomised, double-blind studies (PALLADIUM and QUARTZ) of different durations evaluated the safety and efficacy of Atecert Breezhaler in adult and adolescent patients with persistent asthma.

The PALLADIUM study was a 52-week pivotal study evaluating Atecert Breezhaler 125 mcg/127.5 mcg once daily (N=439) and 125 mcg/260 mcg once daily (N=445) compared to mometasone furoate 400 mcg once daily (N=444) and 800 mcg per day (given as 400 mcg twice daily) (N=442), respectively. A third active control arm included subjects treated with salmeterol/fluticasone propionate 50 mcg/500 mcg twice daily (N=446). All subjects were required to have symptomatic asthma (ACQ-7 score ≥1.5) and were on asthma maintenance therapy using an inhaled synthetic corticosteroid (ICS) with or without LABA for at least 3 months prior to study entry. At screening, 31% of patients had history of exacerbation in the previous year. At study entry, the most common asthma medications reported were medium dose of ICS (20%), high dose of ICS (7%) or low dose of ICS in combination with a LABA (69%).

The primary objective of the study was to demonstrate superiority of either Atecert Breezhaler 125 mcg/127.5 mcg once daily over mometasone furoate 400 mcg once daily or Atecert Breezhaler 125 mcg/260 mcg once daily over mometasone furoate 400 mcg twice daily in terms of trough FEV₁ at week 26.

At week 26, Atecert Breezhaler 125 mcg/127.5 mcg and 125 mcg/260 mcg once daily both demonstrated statistically significant improvements in trough FEV₁ and Asthma Control Questionnaire (ACQ-7) score compared to mometasone furoate 400 mcg once or twice daily, respectively (see Table 2). Findings at week 52 were consistent with week 26.

Atecert Breezhaler 125 mcg/127.5 mcg and 125 mcg/260 mcg once daily both demonstrated a clinically meaningful reduction in the annual rate of moderate or severe exacerbations (secondary endpoint), compared to mometasone furoate 400 mcg once and twice daily (see Table 2).

Results for the most clinically relevant endpoints are described in Table 2.

Lung function, symptoms and exacerbations

Table 2 Results of primary and secondary endpoints in PALLADIUM study at weeks 26 and 52

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Time point/Duration</th>
<th>Atecert Breezhaler¹ vs MF²</th>
<th>Atecert Breezhaler¹ vs SAL/FP³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Medium dose vs medium dose</td>
<td>High dose vs high dose</td>
<td>High dose vs high dose</td>
</tr>
<tr>
<td>Lung function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trough FEV₁</td>
<td>Week 26 (primary endpoint)</td>
<td>211 ml &lt;0.001 (167, 255)</td>
<td>132 ml &lt;0.001 (88, 176)</td>
</tr>
<tr>
<td>Treatment difference P value (95% CI)</td>
<td>Week 52</td>
<td>209 ml &lt;0.001 (163, 255)</td>
<td>136 ml &lt;0.001 (90, 183)</td>
</tr>
<tr>
<td>Mean morning peak expiratory flow (PEF)*</td>
<td>Week 52</td>
<td>30.2 l/min (24.2, 36.3)</td>
<td>28.7 l/min (22.7, 34.8)</td>
</tr>
<tr>
<td>Treatment difference (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean evening peak expiratory flow (PEF)*</td>
<td>Week 52</td>
<td>29.1 l/min (23.3, 34.8)</td>
<td>23.7 l/min (18.0, 29.5)</td>
</tr>
<tr>
<td>Symptoms</td>
<td>ACQ-7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment difference (key secondary endpoint)</td>
<td>Week 26</td>
<td>-0.248 (&lt;0.001, -0.334, -0.162)</td>
<td>-0.171 (&lt;0.001, -0.257, -0.086)</td>
</tr>
<tr>
<td></td>
<td>Week 52</td>
<td>-0.266 (-0.354, -0.177)</td>
<td>-0.141 (-0.229, -0.053)</td>
</tr>
<tr>
<td>ACQ responders (percentage of patients achieving minimal clinical important difference (MCID) from baseline with ACQ ≥0.5)</td>
<td>Percentage</td>
<td>Week 26</td>
<td>76% vs 67%</td>
</tr>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>Week 26</td>
<td>1.73 (1.26, 2.37)</td>
</tr>
<tr>
<td></td>
<td>Percentage</td>
<td>Week 52</td>
<td>82% vs 69%</td>
</tr>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>Week 52</td>
<td>2.24 (1.58, 3.17)</td>
</tr>
<tr>
<td>Percentage of rescue medication free days*</td>
<td>Treatment difference (95% CI)</td>
<td>Week 52</td>
<td>8.6 (4.7, 12.6)</td>
</tr>
<tr>
<td>Percentage of days with no symptoms*</td>
<td>Treatment difference (95% CI)</td>
<td>Week 52</td>
<td>9.1 (4.6, 13.6)</td>
</tr>
<tr>
<td>Annualised rate of asthma exacerbations**</td>
<td>Moderate or severe exacerbations</td>
<td>AR</td>
<td>Week 52</td>
</tr>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>Week 52</td>
<td>0.47 (0.35, 0.64)</td>
</tr>
<tr>
<td>Severe exacerbations</td>
<td>AR</td>
<td>Week 52</td>
<td>0.13 vs 0.29</td>
</tr>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>Week 52</td>
<td>0.46 (0.31, 0.67)</td>
</tr>
</tbody>
</table>

* Mean value for the treatment duration
** RR <1.00 favours indacaterol/mometasone furoate.
1 Atecutra Breezhaler medium dose: 125 mcg/127.5 mcg od; high dose: 125 mcg/260 mcg od.
2 MF: mometasone furoate medium dose: 400 mcg od; high dose: 400 mcg bid (content doses).
Mometasone furoate 127.5 mcg od and 260 mcg od in Atecutra Breezhaler are comparable to mometasone furoate 400 mcg od and 800 mcg per day (given as 400 mcg bid).
4 Trough FEV₁: the mean of the two FEV₁ values measured at 23 hours 15 min and 23 hours 45 min after the evening dose.

Primary endpoint (trough FEV₁ at week 26) and key secondary endpoint (ACQ-7 score at week 26) were part of confirmatory testing strategy and thus controlled for multiplicity. All other endpoints were not part of confirmatory testing strategy.
RR = rate ratio, AR = annualised rate
od = once daily, bid = twice daily

Pre-specified pooled analysis

Atecutra Breezhaler 125 mcg/260 mcg once daily was also studied as an active comparator in another phase III study (IRIDIUM) in which all subjects had a history of asthma exacerbation requiring systemic corticosteroids in the past year. A pre-specified pooled analysis across the IRIDIUM and PALLADIUM studies was conducted to compare Atecutra Breezhaler 125 mcg/260 mcg once daily to salmeterol/fluticasone 50 mcg/500 mcg twice daily for the endpoints of trough FEV₁ and ACQ-7 at week 26 and annualised rate of exacerbations. The pooled analysis demonstrated that Atecutra Breezhaler improved trough FEV₁ by 43 ml (95% CI: 17, 69) and ACQ-7 score by -0.091 (95% CI: -0.153, -0.030) at week 26 and reduced the annualised rate of moderate or severe asthma exacerbations by 22% (RR: 0.78; 95% CI: 0.66, 0.93) and of severe exacerbations by 26% (RR: 0.74; 95% CI: 0.61, 0.91) versus salmeterol/fluticasone.
The QUARTZ study was a 12-week study evaluating Atecutra Breezhaler 125 mcg/62.5 mcg once daily (N=398) compared to mometasone furoate 200 mcg once daily (N=404). All subjects were required to be symptomatic and on asthma maintenance therapy using a low-dose ICS (with or without LABA) for at least 1 month prior to study entry. At study entry, the most common asthma medications reported were low-dose ICS (43%) and LABA/low-dose ICS (56%). The primary endpoint of the study was to demonstrate superiority of Atecutra Breezhaler 125 mcg/62.5 mcg once daily over mometasone furoate 200 mcg once daily in terms of trough FEV₁ at week 12.

Atecutra Breezhaler 125 mcg/62.5 mcg once daily demonstrated a statistically significant improvement in baseline trough FEV₁ at week 12 and Asthma Control Questionnaire (ACQ-7) score compared to mometasone furoate 200 mcg once daily.

Results for the most clinically relevant endpoints are described in Table 3.

### Table 3  Results of primary and secondary endpoints in QUARTZ study at week 12

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Atecutra Breezhaler low dose* vs MF low dose**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung function</strong></td>
<td></td>
</tr>
<tr>
<td><em>Trough FEV₁ (primary endpoint)</em>**</td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>182 ml</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(148, 217)</td>
</tr>
<tr>
<td><strong>Mean morning peak expiratory flow (PEF)</strong></td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>27.2 l/min</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(22.1, 32.4)</td>
</tr>
<tr>
<td><strong>Evening peak expiratory flow (PEF)</strong></td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>26.1 l/min</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(21.0, 31.2)</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>*ACQ-7 (key secondary endpoint)</td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>-0.218</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(-0.293, -0.143)</td>
</tr>
<tr>
<td>Percentage patients achieving MCID from baseline with ACQ ≥0.5</td>
<td>75% vs 65%</td>
</tr>
<tr>
<td>Percentage of rescue medication free days</td>
<td>8.1</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(4.3, 11.8)</td>
</tr>
<tr>
<td>Percentage of days with no symptoms</td>
<td>2.7</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(-1.0, 6.4)</td>
</tr>
</tbody>
</table>

* Atecutra Breezhaler low dose: 125/62.5 mcg od.
** MF: mometasone furoate low dose: 200 mcg od (content dose).
Mometasone furoate 62.5 mcg in Atecutra Breezhaler od is comparable to mometasone furoate 200 mcg od (content dose).
*** Trough FEV₁: the mean of the two FEV₁ values measured at 23 hours 15 min and 23 hours 45 min after the evening dose.
od = once daily, bid = twice daily
Paediatric population

In the PALLADIUM study, which included 106 adolescents (12-17 years old), the improvements in trough FEV₁ at week 26 were 0.173 litres (95% CI: -0.021, 0.368) for Atectura Breezhaler 125 mcg/260 mcg once daily vs mometasone furoate 800 mcg (i.e. high doses) and 0.397 litres (95% CI: 0.195, 0.599) for Atectura Breezhaler 125 mcg/127.5 mcg once daily vs mometasone furoate 400 mcg once daily (i.e. medium doses).

In the QUARTZ study, which included 63 adolescents (12-17 years old), the Least Square means treatment difference for trough FEV₁ at day 85 (week 12) was 0.251 litres (95% CI: 0.130, 0.371).

For the adolescent subgroups, improvements in lung function, symptoms and exacerbation reductions were consistent with the overall population.

The European Medicines Agency has deferred the obligation to submit the results of studies with indacaterol/mometasone furoate in one or more subsets of the paediatric population in asthma (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

Following inhalation of Atectura Breezhaler, the median time to reach peak plasma concentrations of indacaterol and mometasone furoate was approximately 15 minutes and 1 hour, respectively.

Based on the in vitro performance data, the dose of each of the monotherapy components delivered to the lung is expected to be similar for the indacaterol/mometasone furoate combination and the monotherapy products. Steady-state plasma exposure to indacaterol and mometasone furoate after inhalation of the combination was similar to the systemic exposure after inhalation of indacaterol maleate or mometasone furoate as monotherapy products.

Following inhalation of the combination, the absolute bioavailability was estimated to be about 45% for indacaterol and less than 10% for mometasone furoate.

Indacaterol

Indacaterol concentrations increased with repeated once-daily administration. Steady state was achieved within 12 to 14 days. The mean accumulation ratio of indacaterol, i.e. AUC over the 24-h dosing interval on day 14 compared to day 1, was in the range of 2.9 to 3.8 for once-daily inhaled doses between 60 and 480 mcg (delivered dose). Systemic exposure results from a composite of pulmonary and gastrointestinal absorption; about 75% of systemic exposure was from pulmonary absorption and about 25% from gastrointestinal absorption.

Mometasone furoate

Mometasone furoate concentrations increased with repeated once-daily administration via the Breezhaler inhaler. Steady state was achieved after 12 days. The mean accumulation ratio of mometasone furoate, i.e. AUC over the 24-h dosing interval on day 14 compared to day 1, was in the range of 1.61 to 1.71 for once-daily inhaled doses between 62.5 and 260 mcg as part of the indacaterol/mometasone furoate combination.

Following oral administration of mometasone furoate, the absolute oral systemic bioavailability of mometasone furoate was estimated to be very low (<2%).
**Distribution**

**Indacaterol**
After intravenous infusion the volume of distribution (V_s) of indacaterol was 2,361 to 2,557 litres, indicating an extensive distribution. The *in vitro* human serum and plasma protein binding were 94.1 to 95.3% and 95.1 to 96.2%, respectively.

**Mometasone furoate**
After intravenous bolus administration, the V_s is 332 litres. The *in vitro* protein binding for mometasone furoate is high, 98% to 99% in concentration range of 5 to 500 ng/ml.

**Biotransformation**

**Indacaterol**
After oral administration of radiolabelled indacaterol in a human ADME (absorption, distribution, metabolism, excretion) study, unchanged indacaterol was the main component in serum, accounting for about one third of total drug-related AUC over 24 hours. A hydroxylated derivative was the most prominent metabolite in serum. Phenolic O-glucuronides of indacaterol and hydroxylated indacaterol were further prominent metabolites. A diastereomer of the hydroxylated derivative, an N-glucuronide of indacaterol, and C- and N-dealkylated products were further metabolites identified.

*In vitro* investigations indicated that UGT1A1 was the only UGT isoform that metabolised indacaterol to the phenolic O-glucuronide. The oxidative metabolites were found in incubations with recombinant CYP1A1, CYP2D6 and CYP3A4. CYP3A4 is concluded to be the predominant isoenzyme responsible for hydroxylation of indacaterol. *In vitro* investigations further indicated that indacaterol is a low-affinity substrate for the efflux pump P-gp.

*In vitro* the UGT1A1 isoform is a major contributor to the metabolic clearance of indacaterol. However, as shown in a clinical study in populations with different UGT1A1 genotypes, systemic exposure to indacaterol is not significantly affected by the UGT1A1 genotype.

**Mometasone furoate**
The portion of an inhaled mometasone furoate dose that is swallowed and absorbed in the gastrointestinal tract undergoes extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. In human liver microsomes mometasone furoate is metabolised by CYP3A4.

**Elimination**

**Indacaterol**
In clinical studies which included urine collection, the amount of indacaterol excreted unchanged via urine was generally lower than 2% of the dose. Renal clearance of indacaterol was, on average, between 0.46 and 1.20 litres/hour. Compared with the serum clearance of indacaterol of 18.8 to 23.3 litres/hour, it is evident that renal clearance plays a minor role (about 2 to 6% of systemic clearance) in the elimination of systemically available indacaterol.

In a human ADME study in which indacaterol was given orally, the faecal route of excretion was dominant over the urinary route. Indacaterol was excreted into human faeces primarily as unchanged parent substance (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose). Mass balance was complete with ≥90% of the dose recovered in the excreta.

Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing, ranged from 40 to 52 hours which is consistent with the observed time to steady state of approximately 12 to 14 days.
**Mometasone furoate**

After intravenous bolus administration, mometasone furoate has a terminal elimination $T_{1/2}$ of approximately 4.5 hours. A radiolabelled, orally inhaled dose is excreted mainly in the faeces (74%) and to a lesser extent in the urine (8%).

**Interactions**

Concomitant administration of orally inhaled indacaterol and mometasone furoate under steady-state conditions did not affect the pharmacokinetics of either active substance.

**Linearity/non-linearity**

Systemic exposure of mometasone furoate increased in a dose proportional manner following single and multiple doses of Atecutra Breezhaler 125 mcg/62.5 mcg and 125 mcg/260 mcg in healthy subjects. A less than proportional increase in steady-state systemic exposure was noted in patients with asthma over the dose range of 125 mcg/62.5 mcg to 125 mcg/260 mcg. Dose proportionality assessments were not performed for indacaterol as only one dose was used across all dose strengths.

**Paediatric population**

Atecutra Breezhaler may be used in adolescent patients (12 years of age and older) at the same posology as in adults.

**Special populations**

A population pharmacokinetic analysis in patients with asthma after inhalation of indacaterol/mometasone furoate indicated no significant effect of age, gender, body weight, smoking status, baseline estimated glomerular filtration rate (eGFR) and FEV$_1$ at baseline on the systemic exposure to indacaterol and mometasone furoate.

**Patients with renal impairment**

Due to the very low contribution of the urinary pathway to total body elimination of indacaterol and mometasone furoate, the effects of renal impairment on their systemic exposure have not been investigated (see section 4.2).

**Patients with hepatic impairment**

The effect of indacaterol/mometasone furoate has not been evaluated in subjects with hepatic impairment. However, studies have been conducted with the monotherapy components (see section 4.2).

**Indacaterol**

Patients with mild and moderate hepatic impairment showed no relevant changes in $C_{\text{max}}$ or AUC of indacaterol, nor did protein binding differ between mild and moderate hepatic impaired subjects and their healthy controls. No data are available for subjects with severe hepatic impairment.

**Mometasone furoate**

A study evaluating the administration of a single inhaled dose of 400 mcg mometasone furoate by dry powder inhaler to subjects with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment resulted in only 1 or 2 subjects in each group having detectable peak plasma concentrations of mometasone furoate (ranging from 50 to 105 pg/ml). The observed peak plasma concentrations appear to increase with severity of hepatic impairment; however, the numbers of detectable levels (assay lower limit of quantification was 50 pg/ml) were few.

**Other special populations**

There were no major differences in total systemic exposure (AUC) for both compounds between Japanese and Caucasian subjects. Insufficient pharmacokinetic data are available for other ethnicities or races.
5.3 Preclinical safety data

The non-clinical assessments of each monotherapy and of the combination product are presented below.

Indacaterol and mometasone furoate combination

The findings during the 13-week inhalation toxicity studies were predominantly attributable to the mometasone furoate component and were typical pharmacological effects of glucocorticoids. Increased heart rates associated with indacaterol were apparent in dogs after administration of indacaterol/mometasone furoate or indacaterol alone.

Indacaterol

Effects on the cardiovascular system attributable to the beta2-agonistic properties of indacaterol included tachycardia, arrhythmias and myocardial lesions in dogs. Mild irritation of the nasal cavity and larynx was seen in rodents.

Genotoxicity studies did not reveal any mutagenic or clastogenic potential.

Carcinogenicity was assessed in a two-year rat study and a six-month transgenic mouse study. Increased incidences of benign ovarian leiomyoma and focal hyperplasia of ovarian smooth muscle in rats were consistent with similar findings reported for other beta2-adrenergic agonists. No evidence of carcinogenicity was seen in mice.

All these findings occurred at exposures sufficiently in excess of those anticipated in humans.

Following subcutaneous administration in a rabbit study, adverse effects of indacaterol with respect to pregnancy and embryonal/fetal development could only be demonstrated at doses more than 500-fold those achieved following daily inhalation of 150 mcg in humans (based on AUC0-24 h).

Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-natal developmental rat study at an exposure 14-fold higher than in humans treated with indacaterol. Indacaterol was not embryotoxic or teratogenic in rats or rabbits.

Mometasone furoate

All observed effects are typical of the glucocorticoid class of compounds and are related to exaggerated pharmacological effects of glucocorticoids. Mometasone furoate showed no genotoxic activity in a standard battery of in vitro and in vivo tests.

In carcinogenicity studies in mice and rats, inhaled mometasone furoate demonstrated no statistically significant increase in the incidence of tumours.

Like other glucocorticoids, mometasone furoate is a teratogen in rodents and rabbits. Effects noted were umbilical hernia in rats, cleft palate in mice and gallbladder agenesis, umbilical hernia and flexed front paws in rabbits. There were also reductions in maternal body weight gains, effects on foetal growth (lower foetal body weight and/or delayed ossification) in rats, rabbits and mice, and reduced offspring survival in mice. In studies of reproductive function, subcutaneous mometasone furoate at 15 mcg/kg prolonged gestation and difficult labour occurred, with a reduction in offspring survival and body weight.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule content
Lactose monohydrate

Capsule shell
Gelatin
Printing ink

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store in the original package in order to protect from light and moisture. This medicinal product does not require any special temperature storage conditions.

6.5 Nature and contents of container

Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl metacrylate acrylonitrile butadiene styrene. Needles and springs are made from stainless steel.

PA/Alu/PVC – Alu perforated unit-dose blister. Each blister contains 10 hard capsules.

**Ateuctura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules**

Single pack containing 10 x 1 or 30 x 1 hard capsules, together with 1 inhaler.
Multipacks containing 90 (3 packs of 30 x 1) hard capsules and 3 inhalers.
Multipacks containing 150 (15 packs of 10 x 1) hard capsules and 15 inhalers.

**Ateuctura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules**

Single pack containing 10 x 1 or 30 x 1 hard capsules, together with 1 inhaler.
Multipacks containing 90 (3 packs of 30 x 1) hard capsules and 3 inhalers.
Multipacks containing 150 (15 packs of 10 x 1) hard capsules and 15 inhalers.

**Ateuctura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules**

Single pack containing 10 x 1 or 30 x 1 hard capsules, together with 1 inhaler.
Multipacks containing 90 (3 packs of 30 x 1) hard capsules and 3 inhalers.
Multipacks containing 150 (15 packs of 10 x 1) hard capsules and 15 inhalers.

Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling

The inhaler provided with each new prescription should be used. The inhaler in each pack should be disposed of after all capsules in that pack have been used.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Instructions for handling and use

Please read the full Instructions for Use before using the Aectura Breezhaler.

- **Step 1a:** Pull off cap
- **Step 2a:** Pierce capsule once
  - Hold the inhaler upright.
  - Pierce capsule by firmly pressing both side buttons at the same time.
- **Step 3a:** Breathe out fully
  - Do not blow into the inhaler.
- **Check capsule is empty**
  - Open the inhaler to see if any powder is left in the capsule.
  - If there is powder left in the capsule:
    - Close the inhaler.
    - Repeat steps 3a to 3d.
You should hear a noise as the capsule is pierced. Only pierce the capsule once.

Step 1b: Open inhaler

Step 2b: Release side buttons

Step 3b: Inhale medicine deeply
Hold the inhaler as shown in the picture. Place the mouthpiece in your mouth and close your lips firmly around it.
Do not press the side buttons.
Breathe in quickly and as deeply as you can. During inhalation you will hear a whirring noise.
You may taste the medicine as you inhale.

Remove empty capsule
Put the empty capsule in your household waste. Close the inhaler and replace the cap.

Step 1c: Remove capsule
Separate one of the blisters from the blister card. Peel open the blister and remove the capsule.
Do not push the capsule through the foil.
Do not swallow the capsule.

Step 3c: Hold breath
Hold your breath for up to 5 seconds.

Step 3d: Rinse mouth
Rinse your mouth with water after each dose and spit it out.
Step 1d: 
**Insert capsule**

Never place a capsule directly into the mouthpiece.

---

Step 1e: 
**Close inhaler**

---

**Important Information**

- Atecutra Breezhaler capsules must always be stored in the blister card and only removed immediately before use.
- Do not push the capsule through the foil to remove it from the blister.
- Do not swallow the capsule.
- Do not use the Atecutra Breezhaler capsules with any other inhaler.
- Do not use the Atecutra Breezhaler inhaler to take any other capsule medicine.
- Never place the capsule into your mouth or the mouthpiece of the inhaler.
- Do not press the side buttons more than once.
- Do not blow into the mouthpiece.
- Do not press the side buttons while inhaling through the mouthpiece.
- Do not handle capsules with wet hands.
- Never wash your inhaler with water.
Your Ateuctura Breezhaler Inhaler pack contains:
- One Ateuctura Breezhaler inhaler
- One or more blister cards, each containing 10 Ateuctura Breezhaler capsules to be used in the inhaler

<table>
<thead>
<tr>
<th>Base</th>
<th>Capsule chamber</th>
<th>Side buttons</th>
<th>Mouthpiece</th>
<th>Screen</th>
<th>Blister</th>
</tr>
</thead>
</table>

**Frequently Asked Questions**

**Why didn’t the inhaler make a noise when I inhaled?**
The capsule may be stuck in the capsule chamber. If this happens, carefully loosen the capsule by tapping the base of the inhaler. Inhale the medicine again by repeating steps 3a to 3d.

**What should I do if there is powder left inside the capsule?**
You have not received enough of your medicine. Close the inhaler and repeat steps 3a to 3d.

**I coughed after inhaling – does this matter?**
This may happen. As long as the capsule is empty you have received enough of your medicine.

**I felt small pieces of the capsule on my tongue – does this matter?**
This can happen. It is not harmful. The chances of the capsule breaking into small pieces will be increased if the capsule is pierced more than once.

**Cleaning the inhaler**
Wipe the mouthpiece inside and outside with a clean, dry, lint-free cloth to remove any powder residue. Keep the inhaler dry. Never wash your inhaler with water.

**Disposing of the inhaler after use**
Each inhaler should be disposed of after all capsules have been used. Ask your pharmacist how to dispose of medicines and inhalers that are no longer required.
7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

8. MARKETING AUTHORISATION NUMBER(S)

Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules
EU/1/20/1439/001-004

Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules
EU/1/20/1439/005-008

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules
EU/1/20/1439/009-012

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

30 May 2020

10. DATE OF REVISION OF THE TEXT

ANNEX II

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain

Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 62.5 micrograms mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

10 x 1 capsules + 1 inhaler
30 x 1 capsules + 1 inhaler

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

‘QR code to be included’
Scan for more or visit: www.breezhaler-asthma.eu/atectura

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1439/001</td>
<td>10 x 1 capsules + 1 inhaler</td>
</tr>
<tr>
<td>EU/1/20/1439/002</td>
<td>30 x 1 capsules + 1 inhaler</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Atectura Breezhaler 125 micrograms/62.5 micrograms

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Atecutra Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 62.5 micrograms mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

Multipack: 90 (3 packs of 30 x 1) capsules + 3 inhalers.
Multipack: 150 (15 packs of 10 x 1) capsules + 15 inhalers.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/20/1439/003 90 (3 packs of 30 x 1) capsules + 3 inhalers
EU/1/20/1439/004 150 (15 packs of 10 x 1) capsules + 15 inhalers

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Atectura Breezhaler 125 micrograms/62.5 micrograms

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC
SN
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Aetcuta Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 62.5 micrograms mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

10 x 1 capsules + 1 inhaler. Component of a multipack. Not to be sold separately.
30 x 1 capsules + 1 inhaler. Component of a multipack. Not to be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

‘QR code to be included’
Scan for more or visit: www.breezhaler-asthma.eu/atectura

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

- EU/1/20/1439/003 90 (3 packs of 30 x 1) capsules + 3 inhalers
- EU/1/20/1439/004 150 (15 packs of 10 x 1) capsules + 15 inhalers

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Atecuta Breezhaler 125 micrograms/62.5 micrograms

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INNER LID OF OUTER CARTON OF UNIT PACK AND OF INTERMEDIATE CARTON OF MULTIPACK

1. OTHER

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Insert</td>
</tr>
<tr>
<td>2</td>
<td>Pierce and release</td>
</tr>
<tr>
<td>3</td>
<td>Inhale deeply</td>
</tr>
<tr>
<td>Check</td>
<td>Check capsule is empty</td>
</tr>
</tbody>
</table>

Read the leaflet before use.
## MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

### BLISTERS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td>Atectura Breezhaler 125 mcg/62.5 mcg inhalation powder indacaterol/mometasone furoate</td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
<td>Novartis Europharm Limited</td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
<td>EXP</td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
<td>Lot</td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
<td>Inhalation use only</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Atecutra Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 127.5 micrograms mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

10 x 1 capsules + 1 inhaler
30 x 1 capsules + 1 inhaler

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

‘QR code to be included’
Scan for more or visit: www.breezhaler-asthma.eu/atecutra

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
<table>
<thead>
<tr>
<th>9.</th>
<th><strong>SPECIAL STORAGE CONDITIONS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Store in the original package in order to protect from light and moisture.</td>
</tr>
</tbody>
</table>

| 10. | **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE** |

<table>
<thead>
<tr>
<th>11.</th>
<th><strong>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Novartis Europharm Limited</td>
</tr>
<tr>
<td></td>
<td>Vista Building</td>
</tr>
<tr>
<td></td>
<td>Elm Park, Merrion Road</td>
</tr>
<tr>
<td></td>
<td>Dublin 4</td>
</tr>
<tr>
<td></td>
<td>Ireland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12.</th>
<th><strong>MARKETING AUTHORISATION NUMBER(S)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EU/1/20/1439/005 10 x 1 capsules + 1 inhaler</td>
</tr>
<tr>
<td></td>
<td>EU/1/20/1439/006 30 x 1 capsules + 1 inhaler</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13.</th>
<th><strong>BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lot</td>
</tr>
</tbody>
</table>

| 14. | **GENERAL CLASSIFICATION FOR SUPPLY** |

| 15. | **INSTRUCTIONS ON USE** |

<table>
<thead>
<tr>
<th>16.</th>
<th><strong>INFORMATION IN BRAILLE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atectura Breezhaler 125 micrograms/127.5 micrograms</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17.</th>
<th><strong>UNIQUE IDENTIFIER – 2D BARCODE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2D barcode carrying the unique identifier included.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18.</th>
<th><strong>UNIQUE IDENTIFIER - HUMAN READABLE DATA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PC</td>
</tr>
<tr>
<td></td>
<td>SN</td>
</tr>
<tr>
<td></td>
<td>NN</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Afectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules
indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 127.5 micrograms
mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

Multipack: 90 (3 packs of 30 x 1) capsules + 3 inhalers.
Multipack: 150 (15 packs of 10 x 1) capsules + 15 inhalers.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1439/007</td>
<td>90 (3 packs of 30 x 1) capsules + 3 inhalers</td>
</tr>
<tr>
<td>EU/1/20/1439/008</td>
<td>150 (15 packs of 10 x 1) capsules + 15 inhalers</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Atectura Breezhaler 125 micrograms/127.5 micrograms

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules
indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 127.5 micrograms
mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

10 x 1 capsules + 1 inhaler. Component of a multipack. Not to be sold separately.
30 x 1 capsules + 1 inhaler. Component of a multipack. Not to be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

‘QR code to be included’
Scan for more or visit: www.breezhaler-asthma.eu/atectura

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORITY HOLDING**

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. **MARKETING AUTHORIZATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1439/007</td>
<td>90 (3 packs of 30 x 1) capsules + 3 inhalers</td>
</tr>
<tr>
<td>EU/1/20/1439/008</td>
<td>150 (15 packs of 10 x 1) capsules + 15 inhalers</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Atectura Breezhaler 125 micrograms/127.5 micrograms

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INNER LID OF OUTER CARTON OF UNIT PACK AND OF INTERMEDIATE CARTON OF MULTIPACK**

#### 1. OTHER

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Insert</td>
</tr>
<tr>
<td>2</td>
<td>Pierce and release</td>
</tr>
<tr>
<td>3</td>
<td>Inhale deeply</td>
</tr>
<tr>
<td>Check</td>
<td>Check capsule is empty</td>
</tr>
</tbody>
</table>

Read the leaflet before use.
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTERS

1. **NAME OF THE MEDICINAL PRODUCT**

   Ateclura Breezhaler 125 mcg/127.5 mcg inhalation powder
   indacaterol/mometasone furoate

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Novartis Europharm Limited

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**

   Inhalation use only
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 260 micrograms mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

10 x 1 capsules + 1 inhaler
30 x 1 capsules + 1 inhaler

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

‘QR code to be included’
Scan for more or visit: www.breezhaler-asthma.eu/atectura

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1439/009</td>
<td>10 x 1 capsules + 1 inhaler</td>
</tr>
<tr>
<td>EU/1/20/1439/010</td>
<td>30 x 1 capsules + 1 inhaler</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Ateuctura Breezhaler 125 micrograms/260 micrograms

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Aectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 260 micrograms mometasone furoate.

3. LIST OF EXCIPIENTS

Also contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Inhalation powder, hard capsule

Multipack: 90 (3 packs of 30 x 1) capsules + 3 inhalers.
Multipack: 150 (15 packs of 10 x 1) capsules + 15 inhalers.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from light and moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1439/011</td>
<td>90 (3 packs of 30 x 1) capsules + 3 inhalers</td>
</tr>
<tr>
<td>EU/1/20/1439/012</td>
<td>150 (15 packs of 10 x 1) capsules + 15 inhalers</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Atectura Breezhaler 125 micrograms/260 micrograms

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)**

**1. NAME OF THE MEDICINAL PRODUCT**

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules indacaterol/mometasone furoate

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each delivered dose contains 125 micrograms indacaterol (as acetate) and 260 micrograms mometasone furoate.

**3. LIST OF EXCIPIENTS**

Also contains lactose. See package leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Inhalation powder, hard capsule

10 x 1 capsules + 1 inhaler. Component of a multipack. Not to be sold separately.
30 x 1 capsules + 1 inhaler. Component of a multipack. Not to be sold separately.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.
For use only with the inhaler provided in the pack.
Do not swallow capsules.
Inhalation use

‘QR code to be included’
Scan for more or visit: www.breezhaler-asthma.eu/atectura

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP
The inhaler in each pack should be disposed of after all capsules in that pack have been used.
9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from light and moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/20/1439/011 90 (3 packs of 30 x 1) capsules + 3 inhalers
EU/1/20/1439/012 150 (15 packs of 10 x 1) capsules + 15 inhalers

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Atectura Breezhaler 125 micrograms/260 micrograms

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
## PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INNER LID OF OUTER CARTON OF UNIT PACK AND OF INTERMEDIATE CARTON OF MULTIPACK**

### 1. OTHER

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Insert</td>
</tr>
<tr>
<td>2</td>
<td>Pierce and release</td>
</tr>
<tr>
<td>3</td>
<td>Inhale deeply</td>
</tr>
<tr>
<td>Check</td>
<td>Check capsule is empty</td>
</tr>
</tbody>
</table>

Read the leaflet before use.
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTERS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
</tbody>
</table>
|   | Aectura Breezhaler 125 mcg/260 mcg inhalation powder
|   | indacaterol/mometasone furoate |
| 2. | **NAME OF THE MARKETING AUTHORITYHOLDER** |
|   | Novartis Europharm Limited |
| 3. | **EXPIRY DATE** |
|   | EXP |
| 4. | **BATCH NUMBER** |
|   | Lot |
| 5. | **OTHER** |
|   | Inhalation use only |
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is this leaflet:

1. What Aectura Breezhaler is and what it is used for
2. What you need to know before you use Aectura Breezhaler
3. How to use Aectura Breezhaler
4. Possible side effects
5. How to store Aectura Breezhaler
6. Contents of the pack and other information
Instructions for use of Aectura Breezhaler inhaler

1. What Aectura Breezhaler is and what it is used for

What Aectura Breezhaler is and how it works
Aectura Breezhaler contains two active substances called indacaterol and mometasone furoate.

Indacaterol belongs to a group of medicines called bronchodilators. It relaxes the muscles of the small airways in the lungs. This helps to open the airways and makes it easier for air to get in and out of the lungs. When it is taken regularly, it helps the small airways to remain open.

Mometasone furoate belongs to a group of medicines called corticosteroids (or steroids). Corticosteroids reduce the swelling and irritation (inflammation) in the small airways in the lungs and so gradually ease breathing problems. Corticosteroids also help to prevent attacks of asthma.

What Aectura Breezhaler is used for
Aectura Breezhaler is used regularly as treatment for asthma in adults and adolescents (12 years of age and older).

Asthma is a serious, long-term lung disease where the muscles surrounding the smaller airways become tight (bronchoconstriction) and inflamed. Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough.

You should use Aectura Breezhaler every day and not only when you have breathing problems or other symptoms of asthma. This will ensure that it controls your asthma properly. Do not use this medicine to relieve a sudden attack of breathlessness or wheezing.

If you have any questions about how Aectura Breezhaler works or why this medicine has been prescribed for you, ask your doctor.
2. **What you need to know before you use Atectura Breezhaler**

Follow all the doctor’s instructions carefully.

**Do not use Atectura Breezhaler**
- if you are allergic to indacaterol, mometasone furoate or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.

**Warnings and precautions**
Talk to your doctor, pharmacist or nurse before using Atectura Breezhaler if any of the following applies to you:
- if you have heart problems, including an irregular or fast heartbeat.
- if you have thyroid gland problems.
- if you have ever been told you have diabetes or high blood sugar.
- if you suffer from seizures or fits.
- if you have a low level of potassium in your blood.
- if you have severe liver problems.
- if you have tuberculosis (TB) of the lung, or any long-standing or untreated infections.

**During treatment with Atectura Breezhaler**
**Stop using this medicine and get medical help immediately** if you have any of the following:
- tightness of the chest, coughing, wheezing or breathlessness immediately after using Atectura Breezhaler (signs the medicine is unexpectedly tightening the airways, known as paradoxical bronchospasm).
- difficulty breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives (signs of allergic reaction).

**Children and adolescents**
Do not give this medicine to children below 12 years of age because it has not been studied in this age group.

**Other medicines and Atectura Breezhaler**
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. In particular, tell your doctor or pharmacist if you are using:
- medicines that decrease the level of potassium in your blood. These include diuretics (which increase urine production and can be used to treat high blood pressure, e.g. hydrochlorothiazide), other bronchodilators such as methylxanthines used for breathing problems (e.g. theophylline) or corticosteroids (e.g. prednisolone).
- tricyclic antidepressants or monoamine oxidase inhibitors (medicines used in the treatment of depression).
- any medicines that may be similar to Atectura Breezhaler (contain similar active substances); using them together may increase the risk of possible side effects.
- medicines called beta blockers used to treat high blood pressure or other heart problems (e.g. propranolol) or to treat glaucoma (e.g. timolol).
- ketoconazole or itraconazole (medicines used to treat fungal infections)
- ritonavir, nelfinavir or cobicistat (medicines used to treat HIV infection).

**Pregnancy and breast-feeding**
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will discuss with you whether you can use Atectura Breezhaler.

**Driving and using machines**
It is unlikely that this medicine will affect your ability to drive and use machines.
**Atectura Breezhaler contains lactose**

This medicine contains about 25 mg of lactose per capsule. If you have been told by your doctor that you have an intolerance to some sugars, speak with your doctor before taking this medicine.

3. **How to use Atectura Breezhaler**

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

**How much Atectura Breezhaler to inhale**

There are three different strengths of Atectura Breezhaler capsules. Your doctor will decide which is best for you.

The usual dose is to inhale the content of one capsule each day. You only need to use the medicine once a day. Do not use more than your doctor tells you to use.

You should use Atectura Breezhaler every day, even when your asthma is not troubling you.

**When to inhale Atectura Breezhaler**

Inhale Atectura Breezhaler at the same time each day. This will help control your symptoms throughout the day and night. It will also help you to remember to use it.

**How to inhale Atectura Breezhaler**

- Atectura Breezhaler is for inhalation use.
- In this pack, you will find an inhaler and capsules that contain the medicine. The inhaler enables you to inhale the medicine in the capsule. Only use the capsules with the inhaler provided in this pack. The capsules should remain in the blister until you need to use them.
- Peel the backing away from the blister to open it, **do not push the capsule through the foil**.
- When you start a new pack, use the new inhaler supplied in this new pack.
- Dispose of the inhaler in each pack after all capsules in that pack have been used.
- Do not swallow the capsules.
- **Please read the instructions for use on the other side of this leaflet for more information on how to use the inhaler.**

If your symptoms do not improve

If your asthma is not getting better or if it gets worse after you have started using Atectura Breezhaler, talk to your doctor.

If you use more Atectura Breezhaler than you should

If you accidentally inhale too much of this medicine, contact your doctor or hospital for advice immediately. You may need medical attention.

If you forget to use Atectura Breezhaler

If you forget to inhale a dose at the usual time, inhale one as soon as possible on that day. Then inhale the next dose at the usual time on the next day. Do not inhale two doses on the same day.

If you stop using Atectura Breezhaler

Do not stop using Atectura Breezhaler unless your doctor tells you to. Your asthma symptoms may come back if you stop using it.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Some side effects could be serious**
Stop using Atectura Breezhaler and get medical help immediately if you have any of the following:

**Common:** may affect up to 1 in every 10 people
- difficulty breathing or swallowing, swelling of the tongue, lips, or face, skin rash, itching and hives (signs of allergic reaction).

**Uncommon:** may affect up to 1 in every 100 people
- swelling mainly of the tongue, lips, face or throat (possible signs of angioedema).

**Other side effects**
Other side effects include the following listed below. If these side effects become severe, please tell your doctor, pharmacist or nurse.

**Very common:** may affect more than 1 in 10 people
- sore throat
- runny nose
- sudden difficulty breathing and feeling of tightness in chest with wheezing or coughing

**Common:** may affect up to 1 in every 10 people
- voice alteration (hoarseness)
- blocked nose
- sneezing, cough
- headache
- pain in muscles, bones or joints (signs of musculoskeletal pain)

**Uncommon:** may affect up to 1 in every 100 people
- fast heart beat
- oral thrush (sign of candidiasis)
- high level of sugar in the blood
- muscle spasm
- skin itching
- rash
- clouding of the lens of your eyes (signs of cataract)
- blurred vision

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Atectura Breezhaler**

- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month.
- This medicinal product does not require any special temperature storage conditions.
- Store the capsules in the original blister in order to protect from light and moisture, and do not remove until immediately before use.
- Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. **Contents of the pack and other information**

**What Ateuctura Breezhaler contains**
- The active substances are indacaterol (as acetate) and mometasone furoate.

**Ateuctura Breezhaler 125 micrograms/62.5 micrograms**
Each capsule contains 173 micrograms of indacaterol acetate (equivalent to 150 micrograms of indacaterol) and 80 micrograms of mometasone furoate. The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 125 micrograms of indacaterol and 62.5 micrograms of mometasone furoate.

**Ateuctura Breezhaler 125 micrograms/127.5 micrograms**
Each capsule contains 173 micrograms of indacaterol acetate (equivalent to 150 micrograms of indacaterol) and 160 micrograms of mometasone furoate. The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 125 micrograms of indacaterol and 127.5 micrograms of mometasone furoate.

**Ateuctura Breezhaler 125 micrograms/260 micrograms**
Each capsule contains 173 micrograms of indacaterol acetate (equivalent to 150 micrograms of indacaterol) and 320 micrograms of mometasone furoate. The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 125 micrograms of indacaterol and 260 micrograms of mometasone furoate.

- The other ingredient is lactose monohydrate (see “Ateuctura Breezhaler contains lactose” in section 2).

**What Ateuctura Breezhaler looks like and content of the pack**
In this pack, you will find an inhaler together with capsules in blisters. The capsules are transparent and contain a white powder.
- Ateuctura Breezhaler 125 micrograms/62.5 micrograms capsules have a blue product code “IM150-80” printed above one blue bar on the body with a logo printed in blue and surrounded by two blue bars on the cap.
- Ateuctura Breezhaler 125 micrograms/127.5 micrograms capsules have a grey product code “IM150-160” printed on the body with a logo printed in grey on the cap.
- Ateuctura Breezhaler 125 micrograms/260 micrograms capsules have a black product code “IM150-320” printed above two black bars on the body with a logo printed in black and surrounded by two black bars on the cap.

The following pack sizes are available:
Single pack containing 10 x 1 or 30 x 1 hard capsules, together with 1 inhaler.
Multipacks comprising 3 cartons, each containing 30 x 1 hard capsules together with 1 inhaler.
Multipacks comprising 15 cartons, each containing 10 x 1 hard capsules together with 1 inhaler.

Not all pack sizes may be available in your country.

**Marketing Authorisation Holder**
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**Belgien/Belgique/Belgien**
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

**България**
Novartis Bulgaria EOOD
Тел: +359 2 489 98 28

**Česká republika**
Novartis s.r.o.
Tel: +420 225 775 111

**Danmark**
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

**Deutschland**
Novartis Pharma GmbH
Tel: +49 911 273 0

**Ελλάδα**
Novartis (Hellas) A.E.B.E.
Τηλ: +30 210 281 17 12

**España**
Novartis Farmacéutica, S.A.
Tel: +34 93 306 42 00

**France**
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

**Hrvatska**
Novartis Hrvatska d.o.o.
Tel. +385 1 6274 220

**Lietuva**
SIA Novartis Baltics Lietuvos filialas
Tel: +370 5 269 16 50

**Luxembourg/Luxemburg**
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

**Макарорсзаг**
Novartis Hungária Kft.
Tel.: +36 1 457 65 00

**Malta**
Novartis Pharma Services Inc.
Tel: +356 2122 2872

**Nederland**
Novartis Pharma B.V.
Tel: +31 88 04 52 111

**Norge**
Novartis Norge AS
Tlf: +47 23 05 20 00

**Österreich**
Novartis Pharma GmbH
Tel: +43 1 86 6570

**Пolska**
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

**Portugal**
Jaba Recordati, S.A.
Tel: +351 21 432 95 00

**România**
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01
This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Instructions for Use of Aectura Breezhaler

Please read full instructions for use of Aectura Breezhaler inhaler before use. These instructions are also available by scanning the QR code or visiting www.breezhaler-asthma.eu/atectura

“QR code to be included”.

1. **Insert**
   - Step 1a: Pull off cap

2. **Pierce and release**
   - Step 2a: Pierce capsule once
     - Hold the inhaler upright. Pierce capsule by firmly pressing both side buttons at the same time.
     - You should hear a noise as the capsule is pierced. Only pierce the capsule once.

3. **Inhale deeply**
   - Step 3a: Breathe out fully
     - Do not blow into the inhaler.
     - Check capsule is empty
     - Open the inhaler to see if any powder is left in the capsule.
     - If there is powder left in the capsule:
       - Close the inhaler.
       - Repeat steps 3a to 3d.

4. **Check**
   - Step 3b: Inhale medicine deeply
     - Hold the inhaler as shown in the picture. Place the mouthpiece in your mouth and close your lips firmly around it.
     - Do not press the side buttons.

- Step 2b: Release side buttons

- Check capsule is empty

- Powder remaining

- Empty
Step 1c: Remove capsule
Separate one of the blisters from the blister card. Peel open the blister and remove the capsule. Do not push the capsule through the foil. Do not swallow the capsule.

Breathe in quickly and as deeply as you can. During inhalation you will hear a whirring noise. You may taste the medicine as you inhale.

Step 3c: Hold breath
Hold your breath for up to 5 seconds.

Step 3d: Rinse mouth
Rinse your mouth with water after each dose and spit it out.

Remove empty capsule
Put the empty capsule in your household waste. Close the inhaler and replace the cap.
Step 1d:
**Insert capsule**
Never place a capsule directly into the mouthpiece.

Step 1e:
**Close inhaler**

---

**Important Information**
- Atectura Breezhaler capsules must always be stored in the blister card and only removed immediately before use.
- Do not push the capsule through the foil to remove it from the blister.
- Do not swallow the capsule.
- Do not use the Atectura Breezhaler capsules with any other inhaler.
- Do not use the Atectura Breezhaler inhaler to take any other capsule medicine.
- Never place the capsule into your mouth or the mouthpiece of the inhaler.
- Do not press the side buttons more than once.
- Do not blow into the mouthpiece.
- Do not press the side buttons while inhaling through the mouthpiece.
- Do not handle capsules with wet hands.
- Never wash your inhaler with water.
Your Atecutra Breezhaler Inhaler pack contains:
- One Atecutra Breezhaler inhaler
- One or more blister cards, each containing 10 Atecutra Breezhaler capsules to be used in the inhaler

Frequently Asked Questions

Why didn’t the inhaler make a noise when I inhaled?
The capsule may be stuck in the capsule chamber. If this happens, carefully loosen the capsule by tapping the base of the inhaler. Inhale the medicine again by repeating steps 3a to 3d.

What should I do if there is powder left inside the capsule?
You have not received enough of your medicine. Close the inhaler and repeat steps 3a to 3d.

I coughed after inhaling – does this matter?
This may happen. As long as the capsule is empty you have received enough of your medicine.

I felt small pieces of the capsule on my tongue – does this matter?
This can happen. It is not harmful. The chances of the capsule breaking into small pieces will be increased if the capsule is pierced more than once.

Cleaning the inhaler
Wipe the mouthpiece inside and outside with a clean, dry, lint-free cloth to remove any powder residue. Keep the inhaler dry. Never wash your inhaler with water.

Disposing of the inhaler after use
Each inhaler should be disposed of after all capsules have been used. Ask your pharmacist how to dispose of medicines and inhalers that are no longer required.